Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for
cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as
paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving tipifarnib
together with combination chemotherapy may kill more tumor cells. This phase I/II trial is
studying the side effects and best dose of tipifarnib when given together with combination
chemotherapy and to see how well they work in treating patients with stage II or stage III
breast cancer.